Shanghai Universal Biotech Co

Shanghai Universal Biotech Co Current Assets

The Current Assets of Shanghai Universal Biotech Co (301166.SZ) as of Oct 23, 2026 is 144.88 M CNY. In the previous year, Current Assets was 533.60 M CNY — a change of -72.85% (lower).

Current Assets

144.88 MCNY

YoY

-72.85%

Last updated:

Current Assets of Shanghai Universal Biotech Co is 2025 144.88 M CNY. Current Assets of Shanghai Universal Biotech Co was 2024 533.60 M CNY. It decreases by -72.85% lower compared to the previous year.

The Shanghai Universal Biotech Co Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
307.96 M CNY
Jan 1, 2019
257.53 M CNY
Jan 1, 2020
287.78 M CNY
Jan 1, 2021
387.53 M CNY
Jan 1, 2022
615.94 M CNY
Jan 1, 2023
599.44 M CNY
Jan 1, 2024
533.60 M CNY
Jan 1, 2025
144.88 M CNY
The Shanghai Universal Biotech Co Current Assets history
YEARCurrent AssetsYoY
144.88 MCNY-72.85%
533.60 MCNY-10.98%
599.44 MCNY-2.68%
615.94 MCNY+58.94%
387.53 MCNY+34.66%
287.78 MCNY+11.75%
257.53 MCNY-16.37%
307.96 MCNY+463.99%
54.60 MCNY+51.44%
36.06 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shanghai Universal Biotech Co Stock analysis

What does Shanghai Universal Biotech Co do? Shanghai Universal Biotech Co., Ltd. generates revenue through the provision of life science research services, including the supply of third-party brand life science instruments and consumables, alongside its own independent brand products. The company's life science reagents, such as immunological reagents based on antibodies and antibody-related reagents, molecular biology reagents, cell biology reagents, and biochemical reagents, are primarily sourced from third-party brands with supplementary independent brand offerings. Clients purchasing these products include research institutions and laboratories requiring comprehensive technical services like experimental services and technical support. The company focuses on life science instruments and consumables, covering detection, analysis, and sample preparation, while its comprehensive technical services support the operational needs of its clients. The business model emphasizes third-party brand products as the main supply, with independent brand products serving as a supplement. This approach allows Shanghai Universal Biotech to offer a diverse range of life science reagents and instruments without the need for extensive in-house manufacturing. The company's client base primarily consists of entities within the life science research sector seeking reliable reagents, instruments, and technical support to advance their scientific work. By leveraging third-party brands for core products and developing its own independent brand for supplementary offerings, the company optimizes its product portfolio to meet market demands effectively. Shanghai Universal Biotech's revenue streams are derived from the sale of life science reagents, instruments, and consumables, alongside comprehensive technical services. The life science reagents category includes immunological reagents, molecular biology reagents, cell biology reagents, and biochemical reagents, all of which are supplied through a mix of third-party and independent brands. Instruments and consumables focus on detection, analysis, and sample preparation, catering to the technical needs of research institutions. The comprehensive technical services, such as experimental services and technical support, further enhance the value proposition for clients requiring end-to-end solutions in life science research. Shanghai Universal Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai Universal Biotech Co stock

Current Assets of Shanghai Universal Biotech Co is 144.88 M CNY in 2025.

Current Assets of Shanghai Universal Biotech Co changed from 533.60 M CNY to 144.88 M CNY, representing a -72.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Shanghai Universal Biotech Co since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Shanghai Universal Biotech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Shanghai Universal Biotech Co

All Key Metrics — Shanghai Universal Biotech Co